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High Frequency of Cystic Fibrosis Transmembrane
Regulator Mutation L997F in Patients with Recurrent
Idiopathic Pancreatitis and in Newborns with
Hypertrypsinemia
To the Editor:
Cystic ﬁbrosis (CF) (MIM 219700) is a genetic disease
with multisystem involvement and in which defective
chloride transport across membranes causes dehydrated
secretion. The protein encoded by the CF gene (CFTR)
is a transmembrane conductance regulator. The ability
to detect CFTR mutations has led to the recognition of
its association with a variety of conditions, including
bronchiectasis, sinusitis with polyps, and male infertility
(Estivill et al. 1996). A high frequency of mutations in
the CFTR has more recently been shown in patients with
chronic idiopathic pancreatitis (Sharer et al. 1998) and
in newborns with hypertrypsinemia (Castellani et al.
1999). The exocrine pancreas is almost invariably af-
fected in CF, even if not always with clinical manifes-
tations (Lebenthal et al. 1993). In CF and in idiopathic
pancreatitis, the earliest pathological ﬁnding is probably
pancreatic ductular obstruction due to inspissated se-
cretions (Oppenheimer et al. 1975; De Angelis et al.
1992). Hypertrypsinemia is thought to derive from pan-
creatic ductular obstruction and leakage of trypsinogen
into the bloodstream (Crossley et al. 1979). Therefore,
we postulated that there might be particular CFTR gene
mutations involved in pancreatic ductular obstruction,
as manifested in idiopathic pancreatitis or in neonatal
hypertrypsinemia. Since routine CF mutation testing
may miss rare gene alterations that can occur in these
CF-related pathologies, a complete screening of the
CFTR gene was performed in a group of 32 patients
with idiopathic pancreatitis (14 of whom carried a CF
mutation—the 5T variant—or borderline sweat chloride
level, and 18 of whom were without common CF mu-
tations or any other CF characteristic) and in 49 new-
borns with hypertrypsinemia and normal sweat chlo-
ride (32 of whom had a common CF mutation [some
of these reported by Castellani et al. 1999], and 17 of
whom did not have a common CF mutation). The 27
exons of the CFTR gene and their intronic ﬂanking
regions were analyzed by denaturing gradient-gel elec-
trophoresis (DGGE) and by automatic sequencing, as
described elsewhere (Bombieri et al. 1998).
Aside from some common CFTR mutations, none of
which appeared to be more represented than expected,
in comparison with the CFTR gene mutation distribu-
tion in CF patients in the same population, rare muta-
tions were found in 9 of 32 patients with idiopathic
pancreatitis and in 21 of 49 newborns with hypertryp-
sinemia. Among these rare mutations, L997F was iden-
tiﬁed in 4 (12.5%) of 32 patients with idiopathic pan-
creatitis (genotypes L997F/DF508, L997F/5T, and twice
L997F/no mutation identiﬁed, respectively), and in 4
(8%) of 49 newborns with hypertrypsinemia (geno-
types L997F/G542X, L997F/R553X, L997F/DF508,
and L997F-F1052V phase unknown, respectively). The
cumulative frequency of the L997F mutation in pancre-
atic dysfunction (8 [9.87%] of 81) is signiﬁcantly higher
than that found in normal control individuals (Bombieri
et al. 1998, 2000, and unpublished data) from the same
population (3 [0.97%] of 315; Fisher’s exact test, P =
; odds ratio 11.397 (range 2.95–44.029). L977 is.0002
a highly conserved residue in transmembrane domain 9
among ﬁve species analyzed (Tucker et al. 1992). L997F
was initially reported as a DNA variant (Fanen et al.
1992) and was described in a 5-year-old boy from north-
ern India who presented a borderline sweat chloride
value and features highly suggestive of CF (Cystic Fi-
brosis Genetic Analysis Consortium) and in patients
with disseminated bronchiectasis (Bombieri et al. 2000,
Girodon et al. 1997). Following the guidelines of a recent
consensus statement on the diagnosis of CF (Rosenstein
et al. 1998), we tested for L997F in 100 carriers of
mutation DF 508 (mothers of typical patients with CF)
from the same population as the individuals with pan-
creatitis and hypertrypsinemia; since none of them car-
ried it, L997F is designated as a CF-causing mutation,
according to criterion number 4 in the above-cited article
(Rosenstein et al. 1998). This classiﬁcation implies that
the L997F heterozygotes compounded with common CF
mutations found among the patients with idiopathic
pancreatitis (DF508) and that the hypertrypsinemic new-
borns with negative sweat chloride (DF508, G542X, and
R553X) should be diagnosed as affected by an atypical
form of CF; a close follow-up is indicated for these pa-
tients. In conclusion, these data indicate that CFTR
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L997F is associated with increased susceptibility to pan-
creatic ductular obstruction.
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On the Age of the Most Prevalent Gaucher
Disease–Causing Mutation, N370S
To the Editor:
We have recently described a common origin for the
most prevalent mutation (N370S) observed among
Gaucher disease (GD) patients of Ashkenazi Jewish (AJ)
and Spanish descent (Dı´az et al. 1999). We also esti-
mated the age of this mutation, using a formula de-
scribed by Risch et al. (1995b). Unfortunately, as R.
Colombo pointed out in a recent report (Colombo
2000), there was an error in the formula presented in
the original publication that was never rectiﬁed. In a
reply (Risch et al. 1995a) to criticisms raised by Zooss-
mann-Diskin (1995), Risch et al. made no mention of
an error in the formula. The continued application of
the formula by researchers who may not be well versed
in the ﬁeld may lead to repeated mistakes if the error
remains uncorrected. We apologize for our failure to
recognize the error, but we are pleased that it has been
identiﬁed by Colombo, who had no difﬁculty in re-es-
timating the age of the mutation, using our data. This
